|
We asked 40 pharma leaders, who should be driving universal anticounterfeiting solutions?
| Pharma |
48% |
| Regulators |
43% |
| Vendors |
9% |
 |
|
|
|
|
|
|
|
|
1 May, 2012 |
|
| In this Issue |
Looking for Success in Emerging Markets? What Is Your Corporate Value Position?
To gain market access in emerging markets, pharma companies face pressure to offer a convincing Corporate Value Proposition (CVP). But what is a robust CVP, and when should it be used? Nigel Thompson reports.
Read more... |
Europe Gets Serious About Geriatric Trials
Much has been said over the past decade or more about the need to involve the elderly more closely in clinical research, but very little has actually changed. Now the European Forum for GCP has announced its determination to act on the issue. More... |
 |
US: Biosimilars Under Threat?
While the FDA continues to develop its guidance for U.S. biosimilars, including a one-day public hearing on May 11, 2012, the basic legal underpinnings of biosimilars in the US may be under threat, as the Supreme Court debates the healthcare law, a large chunk of which includes provisions for biosimilars. More... |
Genzyme Bets on MS
Riding positive data on a late-phase multiple sclerosis drug, Genzyme execs talked up the company’s willingness to go head-to-head against Rebif, EMD Serono and Pfizer’s blockbuster beta interferon. Ben Comer reports. More...
|
| Product Profile |
| NNIT |
 GxP Cloud now with SaaS
With validated GxP applications ready as SaaS in NNIT's GxP Cloud you can save deployment and validation costs as well as time.
 Read more |
| Sciformix |
 Establishing Case Quality Metrics - defining and using quality metrics for adverse events case processing.  Read more
|
| Event Profile |
Global Publication Planning & Clinical Trial Registries Forum
Strategies for Effective and Compliant Data Dissemination and Coordination
11-12 June 2012
Amsterdam, Netherlands
The relationship between journal publications and trial databases is essential for full disclosure of clinical results information to the public. At the Global Publication Planning and Clinical Trial Registries Forum.
 Read more |
|
|
|
|
|
|
